ArticleJournal of hematology & oncology2015
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
Seiichi Okabe et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this paperpooled itcites it